The Changing Goals of CML Therapy

Slides:

Advertisements

Similar presentations

Long Term Follow-Up After Imatinib Cessation for Patients in Deep Molecular Response: The Update Results of the STIM1 Study1 Preliminary Report of the.

Advertisements

Stopping TKI treatment in CML: Who and when

1 Rea D et al. Proc ASH 2014;Abstract 811.

Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Updated Results of the STIM 1 Discontinuation.

Phase III EURO-SKI: Cessation of TKI Therapy Safe, Feasible for Pts Who Achieve Deep Molecular Response New Findings in Hematology: Independent Conference.

Upfront Combination Therapy vs Step-Up Approach for PAH:

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.

Exploring Early Combination Therapy in PAH

The Nurse View Key Insights Along the CML Continuum

This program will include a discussion of off-label treatment not approved by the FDA for use in the United States.

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Perspectives on Triple-Negative Breast Cancer

Optimizing Therapy for Osteoarthritis

Cardiogenic Shock.

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Assessing the Impact: New Data in T790+ NSCLC

Challenges in the Diagnosis of MS: Physician and Nurse Perspectives

New Patient Journeys in Non-small cell lung cancer

Resistant CML: Understanding the Science to Change Outcomes

The Patient Journey to Remission in MDD: A Collaborative Approach

Monitoring Milestones in Patients With Chronic Myeloid Leukemia

The Latest Data on Oral Prostacyclin Therapy in PAH

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Current and Future Goals in the Treatment of Relapsed CLL

Clinical Cases in Glaucoma Treatment

Chronic Myelogenous Leukemia Diagnosis and Treatment

Understanding Statin Metabolism

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Clinical Considerations in Evidence-based Management of GIST

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

Advances in Myeloid Malignancies

Tailoring Hemophilia Prophylaxis Therapy

The Nurse View: Best Practices in Multiple Myeloma

When Would You Use Single Inhaler Triple Therapy in COPD?

Counseling Patients About Germline BRCA Mutations

What's New in Dyslipidemia?

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

Case Collection in RA: Highlights of an Interactive Workshop

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Managing Depression is a Team Effort:

Examining the Latest Evidence in PAH

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Debating the Issues in Rheumatoid Arthritis with the Experts: Early Treatment and Targets.

Translating the Latest and Greatest Advances in PAH Into Clinical Practice.

Innovations in Home Care

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

When Is Intrathecal Drug Delivery Appropriate?

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

New ELN Recommendations

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Practical Guidance on the Management of Pan-Negative NSCLC

Crossover for pts meeting ELN 2013 failure criteria

A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.

First-Line FCR: Effect of del(17p) on PFS and OS

Improving Adherence to Antiplatelet Therapy After an ACS Event

The Role of Measurable Residual Disease in AML

Program Goal. Program Goal Disclaimer Overview.

When Is Intrathecal Drug Delivery Appropriate?

Branford S et al. Proc ASH 2013;Abstract 254.

Clinical Considerations in Evidence-based Management of GIST

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

New Options for the Treatment of Hepatocellular Carcinoma

Translating Data From Trial to Practice

Presentation transcript:

Optimizing Deep Molecular Responses in Patients With Newly Diagnosed CML

The Changing Goals of CML Therapy

Considerations in Selecting a First-Line Treatment Option

Molecular Response With Second-Generation TKI in Higher Risk Patients

Long-Term Outcomes With Second-Generation TKI in Higher Risk Patients

Sustained Molecular Response With Second-Generation TKI

The Value of TFR as a Goal in CML

TFR Proof of Concept: STIM

STIM: Long-Term Follow-Up

Criteria for Restarting Treatment: A-STIM vs STIM

EURO-SKI: Sustained MMR After TKI Discontinuation

EURO-SKI: Identifying Prognostic Factors

Discontinuing Second-Generation TKI: STOP 2G-TKI

Discontinuing Second-Generation TKI: DADI

Discontinuing Second-Generation TKI: ENESTfreedom

Discontinuing Second-Generation TKI: ENESTop

ENESTop: Subgroup Analysis

Monitoring Response to First-Line TKI: ELN Recommendations

Optimizing Outcomes: Adherence, Monitoring, and Achieving Molecular Response

Long-Term Monitoring and Considerations for TKI Discontinuation

Molecular Monitoring After TKI Discontinuation

Anticipating and Managing AEs With TKIs

Management Considerations After TKI Discontinuation

Conclusions

Abbreviations

Abbreviations (cont)